Finance

Lists
Why is MANKIND down 3,07%?
Dive Deeper
MANKIND:NSE
Mankind Pharma Ltd
2 275,50 INR
-3,07%
(-72,10) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MANKIND...
Open
2 349,90 INR
High
2 354,40 INR
Low
2 268,70 INR
Mkt. cap
937,40 млд
Avg. vol.
483,95 миң
Volume
889,73 миң
P/E ratio
46,04
52-wk high
2 642,00 INR
52-wk low
1 909,70 INR
EPS
49,42 INR
No. of employees
20 миң
Open
2 349,90 INR
High
2 354,40 INR
Low
2 268,70 INR
Mkt. cap
937,40 млд
Avg. vol.
483,95 миң
Volume
889,73 миң
P/E ratio
46,04
52-wk high
2 642,00 INR
52-wk low
1 909,70 INR
EPS
49,42 INR
No. of employees
20 миң
News stories
From web sources and news partners
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Employees20,5 миң
Founded1991
Headquarters-
SectorPharmaceutical industry
Next call 8 күндөн кийин
26-окт., дүй., 14:30
Fiscal period
Q2 2027
- / 14,77 INR
Revenue / Est. (INR)
- / 41,66 млд
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
36,97 млд
35,67 млд
34,43 млд
40,31 млд
Cost of goods sold
10,62 млд
9,78 млд
11,71 млд
10,98 млд
Cost of revenue
10,62 млд
9,78 млд
11,71 млд
10,98 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,25 млд
8,24 млд
15,80 млд
9,14 млд
Operating expense
19,35 млд
18,92 млд
14,77 млд
21,02 млд
Total operating expenses
29,98 млд
28,70 млд
26,48 млд
32,00 млд
Operating income
7,00 млд
6,97 млд
7,95 млд
8,30 млд
Other non operating income
918,70 млн
727,50 млн
-2,31 млд
450,00 млн
EBT including unusual items
6,24 млд
5,09 млд
6,59 млд
7,69 млд
EBT excluding unusual items
6,24 млд
6,16 млд
5,59 млд
7,69 млд
Income tax expense
1,04 млд
951,20 млн
997,50 млн
1,95 млд
Effective tax rate
16,64%
18,69%
15,13%
25,39%
Other operating expenses
8,88 млд
8,46 млд
-3,26 млд
9,63 млд
Net income
5,12 млд
4,09 млд
5,54 млд
5,68 млд
Net profit margin
13,84%
11,46%
16,10%
14,09%
Earnings per share
12,38
11,99
13,89
13,74
Interest and investment income
-
-
580,50 млн
-
Interest expense
-1,70 млд
-1,57 млд
-1,36 млд
-1,10 млд
Net interest expenses
-1,70 млд
-1,57 млд
-778,20 млн
-1,10 млд
Depreciation and amortization charges
2,22 млд
2,23 млд
2,23 млд
2,26 млд
EBITDA
9,20 млд
8,42 млд
9,97 млд
10,33 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору